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Treatment of infantile hemangiomas: therapeutic options in regard to side
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aDepartment of Pediatric Dermatology and Allergology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The
Netherlands; bDepartment of Pediatric Cardiology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The
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dDepartment of Clinical Pharmacy, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands;
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ABSTRACT
Introduction: While options for treatment strategies for infantile hemangiomas (IH) are numer-
ous, evidence-based information about agents, optimal dosage, adverse effects, treatment mod-
ality, pretreatment and treatment strategies remain limited.
Areas covered: To evaluate side effects and adverse events of medical treatment in children with
infantile hemangioma, a comprehensive review of the literature was performed to provide
information for daily practice. In total 254 studies were retrieved from medical databases and
comprised 10,022 patients divided into 5 different treatment groups. Information about working
mechanism, side effects and adverse events of therapies used as a single agent for IH are
discussed and evaluated according to information from pharmacotherapeutic databases.
Randomized controlled trials have only scarcely been performed for the many therapeutic
options reported for IH. Short- and long-term side effects and adverse events, have not been
systematically studied. Subsequently information about the medical treatment options and
pharmacotheraputic databases for therapy in children with IH are incomplete.
Expert opinion: From the many therapeutic options, propranolol is the first-line approach for IH,
predominantly based on clinical observation, efficacy and tolerability in the short-term. The
unsolved ravels of possible short and long-term adverse events of propranolol used during
early developmental stages of children need thorough review.
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Infantile hemangiomas (IH) are the most frequently
observed vascular tumors in infancy, found in 4–10%
of Caucasian infants.[1,2] Several therapeutic regimens
have been used to treat these benign tumors, with
various outcomes. While options for treatment strate-
gies for IH are numerous, evidence-based information
about agents, optimal dosage, treatment modality, pre-
treatment and treatment strategies remains limited. In
addition, side effects and adverse events from treat-
ment of IH are rarely systematically reported.
The study of Léauté-Labrèze et al. published in 2008
demonstrated remarkable treatment results with the
nonselective β-blocker propranolol on IH.[3]
Consensus guidelines for pretreatment evaluation
and monitoring of propranolol therapy for IH were
proposed.[4] Side effects and adverse events reported
in this guideline are bradycardia, hypotension, hypo-
glycemia, bronchospasm and hyperkalemia. In routine
clinical practice, propranolol appears to be effective
for IH, well tolerated and better than previous thera-
pies at inducing regression. These observations, in
conjunction with the immediate availability of the
medication in pediatric formulations, resulted in the
rapid and widespread adoption of propranolol for
treatment of IH. This apparent success may also lead
to a shift in treatment indications from initially func-
tional only to cosmetic indications. Considering the
potential overuse of β-blockers for uncomplicated IH
and the uncertainty about short but especially long-
term potential side effects and adverse events
prompted us to review literature about what is already
known.
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We aimed to conduct a literature review of all med-
ical therapeutic options for IH in children to provide a
more safe and optimal case-based treatment approach,
as well as monitoring. We specifically studied treatment
mechanism of action, side effects and adverse events.
General information about side effects and adverse
events of these treatment strategies from pharma-
cotherapeutic databases was added. Our aim was to
make treatment recommendations and follow-up pro-
tocols for daily practice and subsequently highlight
gaps that currently exist and that should be addressed
in future clinical studies.
2. Methods
2.1. Data source and search strategy
MEDLINE, Embase and Cochrane Library were searched
in April 2014 for the search terms (treatment OR ther-
apy) AND (hemangioma OR hemangiomas) AND (children
OR infantile OR child OR juvenile OR adolescent OR neo-
nate OR newborn OR infant) and applied data limitation,
starting from January 2008 until May 2014. The refer-
ence management program RefWorks was used for the
saving and de-duplication of the articles.
2.2. Selection criteria
We included studies describing medical treatment for
children aged ≤18 years with IH. The selected studies
had to clearly describe whether side effects or adverse
events had occurred, either with detailed symptoms or
no occurrence. Studies were excluded if they focused
on either surgical or laser treatment or photo- or radio-
therapy. Studies not written in English, Dutch, French or
German were excluded, as were reviews and meta-
analyses.
2.3. Study selection
Three independent researchers (FV, NE and MR) con-
ducted the systematic search. The selection process was
performed as follows:
(1) Screen resulting articles for double publications.
(2) Screen all hits on article type and language
(exclude articles meeting exclusion criteria for
article type or language).
(3) Screen all abstracts on relevance (exclude articles
beyond the scope of this research).
(4) Screen full text on relevance if available
(include articles reporting medical treatment
for children ≤18 years of age with an IH and
reporting side effects and adverse events), and
if full text was not available, but all necessary
information (i.e. number of patients, medicine,
dose, side effects and adverse events) was
listed in the abstract, the particular publication
was included as well.
(5) Article citation screening (add articles that met
the inclusion criteria).
The researchers compared the articles remaining after
this selection process, and discrepancies between
reviewers were resolved by consensus.
2.4. Data extraction
Two reviewers (FV and MR) listed all included manu-
scripts. Number of patients, type of medication,
dosage side effects and reported adverse events
were registered in a database. If more than one treat-
ment medication was used in a study, data were
selected from the different treatment groups and
listed as separate substudies regarding therapy and
adverse effects from the included study. Available
literature was evaluated for its hierarchy level of evi-
dence (I–V).[5]
2.5. Data analysis
The pediatric hospital pharmacist (YL) analyzed
reported side effects and adverse events of the medica-
tions mentioned in the included articles by using
national and international pharmacotherapeutic adult
databases.[6–10] The pharmacist added possible serious
side effects and adverse events of used medications
that were not reported in the systematic literature
search.
Article highlights
● Many therapeutic options are reported for infantile heman-
gioma (IH); currently, β-blocker therapy is the first-line treat-
ment option for IH in children.
● The wide range of seemingly effective medical therapies for IH
are merely lacking high level of evidence.
● Therapies utilized demonstrate numerous side effects and
adverse events known for their effect during therapy, while
long-term outcome and sequelae are unknown in IH patients.
● Pharmacotherapeutic databases are incomplete in information
regarding the treatment options in children with IH.
● Current therapeutic strategies used in children during their
early developmental growth need a thorough review of side
effects and adverse events in the short- and long term.
This box summarizes key points contained in the article.



























Initially, 1969 potential eligible studies were identified
in the literature search. After excluding double reports,
1287 unique articles remained. A total of 254 studies
met all inclusion criteria for this review (Figure 1 [11]).
No third-party arbitration was needed for the discre-
pancies between reviewers.
3.2. Patients and treatment
In these 254 studies, a total of 10,022 patients were
included (Table 1). All references are available as an
online supplement. Six studies were case–control or
retrospective comparative studies (3%), 2% were rando-
mized controlled trials (n = 4 level I, n = 2 level II) and
all other were case reports and case series from retro-
spective or prospective cohorts (levels III and IV).
From the included studies, subgroups of patients
were made to deduct combination therapy from sin-
gle-agent therapy. In total, 285 studies were revealed,
with single agents in 254 studies (n = 9172 patients),
covering five different treatment groups for IH (β-block-
ers, corticosteroids, angiotensin-converting enzyme
(ACE) inhibitors, immune modulators and chemother-
apy). Combination therapy was found in 31 studies
(n = 850 patients). Therapies included oral, topical,
intralesional and intravenous modalities. The number
of patients in all studies ranged from 1 to 2013. Over
56% of all patients were treated with oral propranolol
as a single agent (n = 5621). Oral prednisone was used
solitary in 722 patients (7%) and topical imiquimod in
709 patients (7%). All reported side effects and adverse
events were stratified per drug, therapy modality and
evaluated according to adult pharmacotherapeutic
databases (Tables 1 and 2). Some side effects and
adverse events from therapy could not be found in
these databases. Results from the former mentioned
therapy groups used as a single agent (n = 254 studies)
are discussed in more detail.
3.3. β-Blockers
3.3.1. Propranolol
Two randomized trials were identified that supported
efficacy of propranolol, one from the search and one
while performing this study.[12,13] The nonselective
lipophilic β-receptor antagonist propranolol acts by
inhibition of both β-1 and β-2 adrenoreceptors.[14] It
is both effective during the proliferative and the involu-
tion phase of IH growth. The mechanism of action of
propranolol in IH is not yet completely understood, but
it is thought to originate from several effects, like vaso-
constriction,[2,15] inhibition of angiogenesis,[16–23] sti-
mulation of apoptosis [24] and inhibition of the renin–
angiotensin system (RAS).[25,26] Adverse effects of oral
propranolol reported in 167 studies varied from cardio-
vascular events, respiratory symptoms, gastrointestinal













Reasons for inclusion: 
- Studies between 
2008-2014 
- Children study 
population 
- Medical treatment of 





Reasons for exclusion (n =1051): 
- Other conditions than IH  
- No adverse events reported  
- Surgical or laser treatment  
- Photo- or radiotherapy 
- Review/meta-analysis  
- Adult study population  
- Animal studies 
- other languages
Citation screening 
and other sources 
(n = 18)
236
Figure 1. Flow chart according to the four-phase flow diagram of PRISMA. IH: infantile hemangioma.
*Date of search: April 2014.
**When full text was not available, but all necessary information (i.e. number of patients, medicine, dose, adverse effects) was listed
in the abstract, this particular publication was included.



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































central nervous system (CNS) symptoms. Intralesional
propranolol studies (n = 4) showed symptoms due to
pain at the injection site and redness of the skin, while
topical propranolol studies (n = 5) revealed no adverse
effects.
3.3.2. Atenolol
Itinteang et al. suggested that propranolol acts via the
RAS in regulating accelerated involution of proliferating
IH by decreasing renin production in the kidneys.[25] As
the kidneys predominantly express β-1 receptors, the
renin–angiotensin–aldosterone system (RAAS) is most
likely one of the missing links in understanding the
working mechanism of both β-blockers and ACE inhibi-
tors in the treatment of IH.[27] Atenolol is a hydrophilic
β-blocker, acting on β-1 receptors with a proven efficacy
in the treatment of IH.[28,29] Another explanation for
the effect of atenolol could be the limited β-2-blocking
potential of atenolol.[30] In the studies used in this over-
view, the reported side effects and adverse events noted
were hypotension, sleep disturbance, constipation, diar-
rhea, cold extremities and vomiting.
3.3.3. Timolol
Timolol is a nonselective lipophilic β-blocker that is
comparable to propranolol in mechanism of action.
While timolol is available as a liquid gel, it can be
topically administered to superficial IH as can propra-
nolol cream.[31] Topical application reveals limited sys-
temic absorption, and therefore, systemic side effects
and adverse events are uncommon. However, Weibel
et al. showed that 83% of children treated with topical
timolol had urinary timolol excretion, suggestive of
systemic uptake.[32] One study reported sleeping dis-
turbance in one patient, which is also suggestive of
systemic side effects of topical administration.[33] One
randomized trial with 41 patients with superficial IH
revealed effectiveness of timolol without significant dif-
ferences in heart rate or blood pressure measurements
compared to placebo.[34]
3.4. Corticosteroids
Although corticosteroids have been the basis of treat-
ment in IHs for half a century, little is known about the
exact working mechanism in IH. It is suggested that
dexamethasone suppresses vasculogenesis of heman-
gioma-derived stem cells in vitro and corticosteroids
diminish secretion of vascular endothelial growth factor
(VEGF)-A from these stem cells in vitro.[35] A decrease
in VEGF-A can sufficiently suppress vasculogenesis of
hemangioma-derived stem cells in vivo. Corticosteroids
are not able to suppress VEGF-A if it is from
hemangioma-derived endothelial cells from human
umbilical cords.[35] VEGF-A was detected in the prolif-
erative phase of IH, but not in the involution phase. This
might explain why corticosteroids are most effective
during the proliferative phase of the IH.
Corticosteroids can be used systemically, intralesional
and as a topical treatment for IH. One randomized trial
is known for the effectiveness of corticosteroids in IH in
comparison to propranolol versus both.[36] The conclu-
sion was that prednisolone was associated with a
higher number of complications, thereby decreasing
patient compliance. Propranolol showed a consistent,
rapid therapeutic effect compared to prednisolone. A
combination of the two had a comparable but not
superior efficacy than propranolol alone. Another ran-
domized controlled trial by Baumann et al. revealed a
similar efficacy of both drugs.[37] Prednisolone showed
a faster response rate while propranolol was better
tolerated with significantly fewer severe short-term
adverse events. In this review, side effects and adverse
events of systemically used corticosteroids were seen in
20 studies with a total of 722 patients and included
symptoms of metabolic, cardiovascular, endocrine, gas-
trointestinal, infectious, respiratory, CNS and dermato-
logical origin. Intralesional corticosteroid therapy
showed local skin symptoms varying from skin atrophy
to necrosis, but it also revealed systemic side effects
and adverse events (cushingoid appearance, failure to
thrive, adrenal insufficiency with transient reductions of
weight and linear growth, infection, hypertension).
3.5. ACE-inhibitors
The RAAS is involved in the proliferative phase of IH
growth. This is supported by the observation of the nega-
tive action of propranolol on renin or the suppression of
ACE by ACE-inhibitors like captopril. Both actions result in
diminished production of angiotensin 2 and a subsequent
regression of IH.[25] Sinaiko et al. found elevated levels of
renin in children treated with ACE-inhibitors, suggesting
that suppression of renin by β-blockers in addition to ACE-
inhibition creates an even larger effect on IH regression.
[25,38] No further evidence in literature could be found
for this therapy. Adverse effects in this overview came
from one study with eight patients showing a transient
mild creatinine elevation in the first week of treatment in
one of the patients.[27]
3.6. Immune modulators
3.6.1. Imiquimod (topical)
Imiquimod is known to influence the immune system
by induction of cytokine synthesis and thereby

























stimulating secretion of cytokines from macrophages,
monocytes and keratinocytes in the epidermis. These
cytokines, interferon (IFN), tumor necrosis factor − and
interleukins (ILs) lead to a reduction of pro-angiogenic
factors, cell death in endothelial cells and to a
decreased tumor invasion and cell motility.[39]
Furthermore, IL-12 is known for its inhibition of the
angiogenesis in vivo and tube forming of endothelial
cells in vitro.[40] Studies in mice revealed that imiqui-
mod could result in a decreased activity of matrix
metalloproteinase-9.[39] Therefore, the mechanism of
action of imiquimod is ascribed to a cascade that results
in the synthesis of cytokines that inhibit growth of IH.
[41] We identified no evidence-based trials in IH. We
included 10 papers with a total of 709 IH patients
treated with imiquimod. Adverse effects reported were
both local skin reactions and systemic symptoms of
fever and gastrointestinal complaints.
3.6.2. Interferon-
INF-α is a cytokine that suppresses the growth of IH by
inhibition of angiogenesis.[42] In IH, INF-α-2a and -2b
are used subcutaneously. INF-α influences vessel
growth by diminishing the fibroblast growth factor
production or downregulation of IL-8 and the VEGF
gene expression. INF-α acts on the endothelial cells
directly by both impairment of proliferation and migra-
tion. Indraccolo et al. reported that INF-α reduces gene
expression of endothelial cells and thereby contributing
to an increase of negative regulators of angiogenesis.
[43] In 58 patients using IFN-− injections for IH, several
adverse effects were reported; gastrointestinal, meta-
bolic disturbances but also general symptoms such as
fever, fatigue, hair loss and flu-like symptoms.
3.6.3. Sirolimus
Mammalian target of rapamycin (mTOR) acts as a mas-
ter switch for numerous cellular processes including
angiogenesis and cell growth.[44] Sirolimus is an
mTOR inhibitor and could therefore be beneficial in
the treatment of vascular anomalies.[45] In a case
report with only one patient, several side effects and
adverse events occurred (hypertriglyceridemia, febrile
neutropenia and mild mucositis).[46]
3.7. Chemotherapy
3.7.1. Bleomycin (intralesional)
Bleomycin is a cytotoxic agent that is able to degrade
deoxyribonucleic acid (DNA), which results in an inhibi-
tion of cell replication, cell growth and DNA synthesis in
tumor biology. It is used for intralesional treatment in
IH. This sclerosing agent acts on vascular endothelium
by induction of cell injury and disperse endothelial cells,
leading to occlusion of blood vessels. Overall, it stimu-
lates apoptosis of rapidly dividing cells, as is seen in
proliferating IH.[47] The literature is limited for retro-
spective and prospective case studies only. In three
studies of bleomycin-only intralesional therapy for IH,
side effects and adverse events in 123 patients con-
sisted of local symptoms at the injection site, but also
systemic gastrointestinal complaints.
3.7.2. Vincristine
The vinca-alkaloid vincristine is known for its systemic
chemotherapeutic action in malignancies. It negatively
influences vascular and endothelial cell growth, indu-
cing apoptosis and is furthermore able to stop mitosis
by inhibiting the formation of microtubules.[48]
Evidence-based trials with vincristine in IH are not avail-
able. Vincristine was used in two reports with eight
patients of IH and reported side effects were due to
infectious and peripheral nervous system origin.
3.7.3. Cyclophosphamide
Cyclophosphamide is an alkylating agent affecting DNA
and the cell cycle process. It is furthermore known for
its immunosuppressive effect on B and T cells.[6] One
case with diffuse neonatal hemangiomatosis was trea-
ted with cyclophosphamide and suffered from fever,
sepsis, catheter infection and hypertension.[49]
4. Discussion
A proper diagnosis of IH should be obtained before
starting any therapy. Although this statement is beyond
the scope of this report, it is especially true for initiating
systemic therapy for IH with potential side effects and
adverse events. This review focuses specifically on
reported side effects and adverse events of any medical
treatment strategy in IH. This comprehensive overview
of literature was performed by stratification of all
reported side effects and adverse events per drug and
treatment modality instead of by frequencies in
patients. The outcome demonstrates that IH are treated
with a wide range of medications. In total, 10,022
patients treated in five different single-treatment med-
ication groups for IH were included. Randomized con-
trolled trails have only scarcely been performed for any
of the reported treatment strategies. Short- and long-
term side effects and adverse events are even less well
studied. Pharmacotherapeutic databases are incom-
plete in information regarding the treatment options
in children with IH.
Corticosteroids are well known for their adverse
effects and are therefore no longer considered a first-

























line treatment in pediatric IH. β-Blockers have become
the first-line treatment modality for complicated
hemangiomas. They appear to be more successful
than corticosteroids, also beyond the proliferative
phase,[50] while they have less side effects, although
short and especially long-term adverse events are not
systematically studied. The lipophilic nonselective char-
acter of propranolol causes cardiovascular, respiratory
and CNS adverse effects. While the hydrophilic and
more selective β-blocker atenolol is a promising alter-
native, its efficacy, side effects and adverse events spec-
trum have not been studied as extensively yet.[27–
29,51–53] Topical β-blocker treatment possibly has
less systemic adverse effects but it seems to be effective
only in superficial IH.[31] ACE-inhibition seems to be a
good alternative by its action mechanism, although
literature is very limited and renal adverse effects at
young age can be harmful.[27] Chemotherapy and
immune modulator therapies have also been studied
but are known for serious side effects and are currently
replaced by less harmful strategies that appear to have
at least similar effectiveness.
Tables 3 and 4 show effective therapies in children
with IH, according to literature with dosage, pretreat-
ment and treatment strategies. In addition, they depict
common, unusual, serious and harmless side effects
and adverse events. This overview might be helpful
for the treating physician making a deliberate indivi-
dualized or case-based choice for any patient with
complicated IH according to current knowledge at any
point during treatment. Moreover, we hope this review
will be an impetus for further research since especially
long-term side effects in this young patient population
are unknown. While Table 3 focuses on first- and sec-
ond-line therapy, Table 4 shows therapies that should
only be used in case of severe complicated IH not
responding to first- or second-line therapy. After con-
sulting a vascular expert team, first-line therapy can be
used in general practice, according to a standardized
protocol. Second- and third-line therapy for IH though
should be indicated and coordinated by a multidisci-
plinary team with expert knowledge on vascular
abnormalities in children. Systemic immune modulator
and chemotherapy medication are currently only indi-
cated in severe complicated IH not responding to any
other treatment and should exclusively be under team
expert auspices. In the absence of evidence-based lit-
erature, it is hard to judge the most efficacious and
safest therapy from the reviewed options.
The results of the conducted review have limita-
tions by the low levels of evidence of included stu-
dies, small sample size for some therapy modalities,
lack of available data on especially systematically
studied side effects and adverse events and absence
of longitudinal follow-up studies. Current review
shows the side effects and adverse events listed by
therapy without any denominator, which is a limita-
tion that might leave the clinician with many uncer-
tainties. Possibly also side effects and adverse events
are underreported by this conducted review analysis.
Furthermore, propranolol is offered to a much larger
population than corticosteroids ever were, which is
reflected in this overview and accounts for an
unsolved bias. Limitations in the use of pharma-
cotherapeutic databases were due to lack of informa-
tion about specific treatment options for IH and the
fact that derived information is from treated adults
mostly for other indications. Several of the observed
side effects and adverse events in the pediatric IH
population are not reported in adult pharmacothera-
peutic databases. This shows that the available data-
bases currently are incomplete and should be
updated. This is of importance to all professionals
participating in the care of IH patients.
In conclusion, there is a wide range of seemingly
effective medical therapies for IH, although high level
of evidence is still limited. Therapies utilized demon-
strate numerous side effects and adverse events merely
known for their effect during therapy, while long-term
outcome and sequelae are unknown in these patients.
In order to guide the clinician to judge the most effica-
cious and safest therapy for an individual patient, the
list of therapeutic options for IH in children was
reviewed. To date, first-line treatment in patients with
IH is β-blocker therapy. This approach is based on
clinical observation, efficacy and tolerability of propra-
nolol, especially in the short term. Considering potential
overuse of β-blockers for uncomplicated IH and the
uncertainty about long-term potential side effects and
adverse events still makes critically weighing the treat-
ment indication and more comprehensive review stu-
dies of great importance.
5. Expert opinion
The first- line approach with propranolol for IH seems to
be predominantly based on clinical observation, effi-
cacy and tolerability in the short term. Only 7 years
after the first report of Léauté-Labrèze et al. [3], little
is known about the long-term outcome and safety. The
recently performed randomized controlled trial by
Léauté-Labrèze [13] showed that propranolol was effec-
tive at a dose of 3 mg/kg/day for 6 months for IH. It
revealed a safety assessment by analysis of adverse
events, which according to the authors included neu-
rodevelopment revealed no notable differences




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































between the propranolol treatment arms and the pla-
cebo group. Unfortunately, the report does not specify
in detail what variables were studied with regard to
neurodevelopment and follow-up time was relatively
short. The qualification of propranolol as a safe treat-
ment strategy for IH in pediatric patients should there-
fore be interpreted with caution.
To date, detailed assessment of cardiovascular, gross
motor and neurocognitive development has not yet been
published in IH patients treated with propranolol.
Subsequently, short- and long-term development out-
come of treated infants with IH is unknown. Only one
very recent study by Moyakine et al. showed that in 103
patients with IH treated with propanolol no evidence of
psychomotor developmental delay was found.[54] It
remains possible though, the authors concluded, that
propranolol treatment causes subtle adverse effects,
which cannot be traced with tools such as the van
Wiechen scheme. And as such, they suggest that future
prospective studies using universal screening tools such
as the Parents Evaluation of Developmental Status, the
Ages and Stages Questionnaire or more advanced neu-
ropsychological tests are needed to support their find-
ings. Kwon et al. reported on the analyses of infants
treated with propranolol for various indications, including
IH.[55] It demonstrated that no serious adverse events
resulted in hospitalization and supported the perceived
safety profile of propranolol. Results also implied that
serious adverse events might be delayed and thus not
detected during initiation of the drug treatment. It is
unknown whether young infants with IH and a normo-
tensive cardiovascular system have a different complica-
tion risk of propranolol therapy compared to those infants
treated with propranolol for cardiac indications. Data on
long-term outcome of patients treated with β-blockers for
other indications than IH, for example, patients with
arrhythmic diseases, are lacking in literature. Another con-
cern is the observation by Gonski, who noted that 4 of 84
IH patients with oral propranolol for IH demonstrated a
delay in unassisted walking.[56] In support of this, Langley
summarizes many associated CNS effects of propranolol,
including a meta-analysis of Lonergan, showing propra-
nolol treatment negatively influences recall of emotional
material.[57,58]We endorse the concern raised by Langley
about the unknown significance of CNS effects resulting
from propranolol use in IH patients during early develop-
mental stages and/or for prolonged periods of therapy.
This concern is confirmed in adult literature revealing a
reduction in subsequent memory for both new and pre-
viously learned emotional material and an impairment of
mood and sleep quality by propranolol.[58–60]
These findings suggest that this current therapeutic


















































































































































































































































































































































































































































































































































































































































































































side effects and adverse events in short and especially long
term to judge β-blocker therapy in its safety. The possibility
to exchange the long-term sequelae of high-dose predni-
sone into acceptable short-term adverse events of propra-
nolol seemed more important than the unsolved ravels of
possible long-term adverse events of propranolol. It is
imperative that these unsolved ravels need thorough
review during early developmental stages and especially
in long-term follow-up studies to judge safety of proprano-
lol. Moreover, in the absence of this information, we are in
favor of withholding propranolol therapy for pure cosmetic
indications.
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